Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
ABBOTT MEDICAL · Decision date Sep 11, 2026
What did the FDA decide?
The FDA record lists supplement P010032/S261 for Abbott Medical, a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, decided OK30 on 2026-09-11. The reported purpose is approval to use an alternate third-tier supplier for the FR-4 material in printed circuit boards for Chargers of the Eterna SCS IPG and Liberta RC DBS IPG. The device category is Stimulator, spinal-cord, totally implanted for pain relief, product code LGW, specialty Neurology.
The P010032 identifier ties this to the original PMA for that spinal-cord stimulator system; the notice covers a supplier change, not a new approval of the system or a new indication. The record does not state which supplier, qualification testing, FR-4 specification, or any safety or effectiveness data, and the OK30 decision reflects the agency's action on the notice rather than independent clinical evidence.
FDA approval order statement
approval to utilize an alternate third-tier supplier for the FR-4 material, which is used in the manufacture of the printed circuit boards for the Chargers of the Eterna SCS IPG and Liberta RC DBS IPG
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S261
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S261 received
Application receipt date recorded by FDA.
P010032/S261 · FDA decision
30-Day Notice
P010032/S251 · Related supplement
Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
P010032/S260 · Related supplement
Proclaim family of SCS IPG
P010032/S265 · Related supplement
Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
P010032/S262 · Related supplement
Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
Proclaim family of SCS IPGP010032/S260 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S261
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





